Stevanato Group (NYSE:STVN) Director Sells 2,023 Shares of Stock

Stevanato Group S.p.A. (NYSE:STVN) Director Luciano Santel sold 2,023 shares of Stevanato Group stock in a transaction on Friday, August 7th. The stock was sold at an average price of €20.09, for a total transaction of €40,642.07. Following the transaction, the director directly owned 4,739 shares of the company’s stock, valued at approximately €95,206.51. This trade represents a 29.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stevanato Group Stock Performance

Shares of STVN traded up €0.38 during trading hours on Monday, hitting €20.65. The company had a trading volume of 501,629 shares, compared to its average volume of 541,629. The firm has a market cap of $6.25 billion, a price-to-earnings ratio of 36.87, a PEG ratio of 1.70 and a beta of 0.77. The business has a fifty day moving average of €18.80 and a 200-day moving average of €16.97. Stevanato Group S.p.A. has a 12 month low of €12.89 and a 12 month high of €28.00. The company has a quick ratio of 1.08, a current ratio of 1.61 and a debt-to-equity ratio of 0.21.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%.The company had revenue of €273.57 million for the quarter. During the same period last year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Equities analysts anticipate that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

Several institutional investors and hedge funds have recently bought and sold shares of the company. GW&K Investment Management LLC increased its holdings in Stevanato Group by 76.2% in the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after buying an additional 1,055 shares during the period. Fifth Third Bancorp raised its position in Stevanato Group by 22.6% during the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after purchasing an additional 773 shares in the last quarter. State of Wyoming lifted its stake in Stevanato Group by 39,216.7% during the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after purchasing an additional 2,353 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Stevanato Group in the 3rd quarter valued at $68,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Stevanato Group by 1,268.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after purchasing an additional 4,250 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Weiss Ratings upgraded Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 16th. TD Cowen raised shares of Stevanato Group to a “strong-buy” rating in a research report on Wednesday, June 17th. Finally, Wolfe Research began coverage on shares of Stevanato Group in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.